Family · Pharmaceutical analytical standards
Palbociclib
The first CDK4/6 inhibitor approved, in 2015, for hormone receptor-positive breast cancer. It blocks the cycle by which tumour cells divide. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?The molecule had already been synthesised in the early 2000s and sat on the shelf for years, before new studies revealed its potential.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
